NBIX vs TECH: stock comparison and AI forecast
Neurocrine Biosciences Inc (NBIX) and Bio-Techne Corp (TECH) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
NBIX Neurocrine Biosciences Inc
- Price
- $146.38 +11.2% · 6M
- Market Cap
- $14.88B
- P/E Ratio
- 21.2x
- Size
- large-cap
- AI Forecast
- NO CURRENT FORECAST
TECH Bio-Techne Corp
- Price
- $72.67 +32.8% · 6M
- Market Cap
- $11.40B
- P/E Ratio
- 62.7x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- NBIX is 1.3 times larger than TECH by market capitalization ($14.88B against $11.40B).
- NBIX trades at 21.2 times trailing earnings, TECH at 62.6 times.
- Over the last six months TECH returned +32.8% and NBIX +11.2%.
- NBIX turns 20.9% of its revenue into net income, against 15.0% for TECH.
- NBIX carries 0.45 times debt per unit of equity, against 0.23 times for TECH.
- TECH yields 0.44% in dividends; NBIX pays none.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | NBIX | TECH |
|---|---|---|
| Market Cap | $14.88B | $11.40B |
| P/E Ratio | 21.18x | 62.65x |
| P/B Ratio | 4.03x | 5.41x |
| Dividend Yield | – | 0.44% |
| EPS | $6.91 | $1.16 |
| Book Value/Share | $36.34 | $13.44 |
| Revenue/Share | $33.19 | $7.75 |
| FCF/Share | $8.56 | $1.68 |
Profitability & Margins
| Metric | NBIX | TECH |
|---|---|---|
| ROE | 19.1% | 8.6% |
| ROA | 13.2% | 7.0% |
| ROIC | 17.7% | 10.4% |
| Gross Margin | 98.4% | 65.8% |
| Operating Margin | 23.6% | 20.7% |
| Net Margin | 20.9% | 15.0% |
| EBT Margin | 27.9% | 19.8% |
| Tax Rate | 25.0% | 24.4% |
Financial Health
| Metric | NBIX | TECH |
|---|---|---|
| Current Ratio | 1.87x | 4.55x |
| Quick Ratio | 1.75x | 3.35x |
| D/E Ratio | 0.45x | 0.23x |
| Financial Leverage | 1.45x | 1.23x |
| Interest Coverage | 56.1x | 28.6x |
| Working Capital | $763M | $581M |
Cash Flow
| Metric | NBIX | TECH |
|---|---|---|
| Operating Cash Flow | $898M | $292M |
| Free Cash Flow | $870M | $263M |
| Capital Spending | -$28M | -$29M |
| OCF Growth YoY | 58.3% | 1.6% |
| FCF Growth YoY | 64.6% | 2.6% |
| FCF/Sales | 25.8% | 21.7% |
| CapEx/Sales | 0.8% | 2.4% |
Operational Efficiency
| Metric | NBIX | TECH |
|---|---|---|
| Asset Turnover | 0.63x | 0.47x |
| Receivables Turnover | 3.8x | 5.6x |
| Inventory Turnover | 0.5x | 2.1x |
| Fixed Assets Turnover | 37.3x | 5.2x |
| Days Sales Outstanding | 96 days | 65 days |
| Days Inventory | 694 days | 172 days |
| Payables Period | 946 days | 23 days |
| Cash Conversion Cycle | -156 days | 213 days |
Income Statement
| Metric | NBIX | TECH |
|---|---|---|
| Total Revenue | $3.37B | $1.22B |
| Operating Income | $795M | $252M |
| Net Income | $706M | $182M |
| R&D Expense | $1.13B | $95M |
| SG&A Expense | $1.35B | $452M |
| Cost of Goods Sold | $55M | $416M |
Dividend & Shareholder Information
| Metric | NBIX | TECH |
|---|---|---|
| Dividends Per Share | – | $0.32 |
| Payout Ratio | – | 27.6% |
| Shares Outstanding | 102M | 157M |
| Net Income Growth | 102.6% | 147.7% |
| EPS Growth | 85.8% | 152.2% |
NBIX vs TECH: stock comparison and AI forecast
Which is bigger, NBIX or TECH?
NBIX is 1.3 times larger than TECH by market capitalization ($14.88B against $11.40B).
Which is cheaper on earnings, NBIX or TECH?
NBIX trades at 21.2 times trailing earnings, TECH at 62.6 times.
Which stock performed better over the last six months, NBIX or TECH?
Over the last six months TECH returned +32.8% and NBIX +11.2%.
Which one does Intratio's AI model rank higher, NBIX or TECH?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.